Beta Bionics (NASDAQ:BBNX) Stock Price Down 3% - Here's Why

Key Points

• Beta Bionics shares fell 3% to about $18.90 in thin trading, with volume down 97% from the average session. The stock remains above its 50-day and 200-day moving averages.
• Analyst sentiment remains broadly positive, with seven Buy ratings and an overall “Moderate Buy” consensus, though Bank of America cut its price target to $11. The average analyst target is $20.10.
• The company exceeded quarterly loss expectations, reporting an adjusted loss of $0.53 per share versus the projected $0.62 loss, alongside $32.01 million in revenue; however, it continues to post negative margins and analysts expect a full-year loss.

Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) shares fell 3% during mid-day trading on Friday . The company traded as low as $18.73 and last traded at $18.90. 40,475 shares were traded during trading, a decline of 97% from the average session volume of 1,166,167 shares. The stock had previously closed at $19.48.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Bank of America lowered their target price on shares of Beta Bionics from $23.00 to $11.00 and set a "neutral" rating on the stock in a report on Monday, May 18th. Truist Financial lifted their price target on shares of Beta Bionics from $18.00 to $22.00 and gave the company a "buy" rating in a report on Monday, July 13th. UBS Group assumed coverage on shares of Beta Bionics in a report on Tuesday, July 28th. They set a "buy" rating and a $22.00 price objective for the company. William Blair started coverage on Beta Bionics in a report on Friday. They issued a "market perform" rating on the stock. Finally, The Goldman Sachs Group increased their price target on Beta Bionics from $17.00 to $19.00 and gave the company a "buy" rating in a research note on Wednesday, July 15th. Seven equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $20.10.

Beta Bionics Trading Down 1.5%

The stock has a market capitalization of $863.36 million, a PE ratio of -11.63 and a beta of 3.13. The business's 50 day moving average is $16.05 and its 200 day moving average is $13.22.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.09. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. The business had revenue of $32.01 million during the quarter. As a group, analysts anticipate that Beta Bionics, Inc. will post -2.1 EPS for the current year.

Insider Activity at Beta Bionics

In other Beta Bionics news, insider Mike Mensinger sold 4,378 shares of the company's stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $12.61, for a total value of $55,206.58. Following the transaction, the insider owned 184,415 shares of the company's stock, valued at $2,325,473.15. This represents a 2.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Stephen Feider sold 6,676 shares of the stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $12.61, for a total value of $84,184.36. Following the completion of the sale, the chief financial officer owned 166,053 shares in the company, valued at approximately $2,093,928.33. The trade was a 3.87% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 36,355 shares of company stock worth $512,943 over the last quarter. 5.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Beta Bionics

A number of institutional investors have recently modified their holdings of the stock. Strs Ohio bought a new position in Beta Bionics in the first quarter worth approximately $29,000. Summit Securities Group LLC bought a new stake in Beta Bionics during the 4th quarter valued at $52,000. Legal & General Group Plc lifted its holdings in shares of Beta Bionics by 197.4% in the 2nd quarter. Legal & General Group Plc now owns 3,976 shares of the company's stock worth $58,000 after buying an additional 2,639 shares during the period. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Beta Bionics by 1,075.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company's stock worth $61,000 after buying an additional 1,818 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Beta Bionics during the 1st quarter worth $95,000.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company's flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics' offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source